293 related articles for article (PubMed ID: 10647762)
21. Low-molecular-weight heparin in the treatment of pulmonary embolism.
Ageno W; Turpie AG
Semin Vasc Surg; 2000 Sep; 13(3):189-93. PubMed ID: 11005462
[TBL] [Abstract][Full Text] [Related]
22. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
[TBL] [Abstract][Full Text] [Related]
23. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
; Büller HR; Gent M; Gallus AS; Ginsberg J; Prins MH; Baildon R
N Engl J Med; 1997 Sep; 337(10):657-62. PubMed ID: 9280815
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
25. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.
Geerts WH; Jay RM; Code KI; Chen E; Szalai JP; Saibil EA; Hamilton PA
N Engl J Med; 1996 Sep; 335(10):701-7. PubMed ID: 8703169
[TBL] [Abstract][Full Text] [Related]
26. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
[TBL] [Abstract][Full Text] [Related]
28. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
29. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
Kearon C
Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
[TBL] [Abstract][Full Text] [Related]
30. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
Daskalopoulos ME; Daskalopoulou SS; Tzortzis E; Sfiridis P; Nikolaou A; Dimitroulis D; Kakissis I; Liapis CD
Eur J Vasc Endovasc Surg; 2005 Jun; 29(6):638-50. PubMed ID: 15878544
[TBL] [Abstract][Full Text] [Related]
32. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
33. Tinzaparin in the treatment of venous thromboembolism.
Pineo GF; Hull RD
Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
[TBL] [Abstract][Full Text] [Related]
35. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
[TBL] [Abstract][Full Text] [Related]
36. Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
Riess H; Becker LK; Melzer N; Harenberg J
Blood Coagul Fibrinolysis; 2014 Dec; 25(8):838-44. PubMed ID: 25004024
[TBL] [Abstract][Full Text] [Related]
37. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
38. New perspectives for treatment of pulmonary embolism.
Simonneau G
Haemostasis; 1998; 28 Suppl 3():95-9. PubMed ID: 10069768
[TBL] [Abstract][Full Text] [Related]
39. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH
J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307
[TBL] [Abstract][Full Text] [Related]
40. Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
Monreal M; Büller H; Lensing AW; Bonet M; Roncales J; Muchart J; Fraile M
Thromb Haemost; 2002 Dec; 88(6):938-42. PubMed ID: 12529742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
